New drug combo aims to shrink lung tumors before surgery

NCT ID NCT07452003

Recruiting now Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Mar 20, 2026 · Last updated May 25, 2026 · Updated 9 times

Summary

This study tests whether giving a new immunotherapy drug (QL1706) along with standard chemotherapy before surgery can help shrink tumors in people with a certain type of lung cancer (non-small cell lung cancer). About 30 adults with stage IIB to IIIB lung cancer will receive the drug combo for three cycles, then have surgery if possible. The main goal is to see how many patients have very little or no cancer left in the removed tissue.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100730, China

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER